Key terms
About SLNO
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SLNO news
Mar 22
7:20am ET
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)
Mar 18
7:00am ET
Analysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)
Mar 15
4:55am ET
Soleno Therapeutics participates in a conference call with Piper Sandler
Mar 07
5:03pm ET
Soleno Therapeutics participates in a conference call with Piper Sandler
Mar 07
7:36am ET
Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus
Mar 07
7:36am ET
Oppenheimer Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)
Mar 07
7:36am ET
Piper Sandler Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)
Mar 07
6:23am ET
Soleno Therapeutics Corrects Q4 Financial Reporting Error
Mar 06
4:29pm ET
Soleno Therapeutics reports Q4 EPS (33c), consensus (27c)
Feb 21
5:55am ET
Soleno Therapeutics management to meet with Oppenheimer
Feb 20
4:55am ET
Soleno Therapeutics management to meet with Oppenheimer
Feb 15
8:42am ET
Soleno Therapeutics management to meet with Oppenheimer
Feb 05
10:10am ET
Charter downgraded, Cigna upgraded: Wall Street’s top analyst calls
Feb 05
4:57am ET
Soleno Therapeutics initiated with an Overweight at Piper Sandler
Feb 05
4:10am ET
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO), Merck & Company (MRK) and Tenet Healthcare (THC)
Jan 24
8:07am ET
Soleno Therapeutics announces appointments to its leadership team
Jan 22
4:10pm ET
Soleno Therapeutics initiated with a Buy at Stifel
Jan 05
8:11am ET
Soleno Therapeutics announces inducement grants under Nasdaq listing rule
Jan 02
4:09pm ET
Soleno Therapeutics files automatic mixed securities shelf
Jan 02
7:40am ET
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO), Agilon Health (AGL) and Integer Holdings (ITGR)
Jan 02
7:37am ET
Soleno Therapeutics price target raised to $47 from $44 at Oppenheimer
Dec 28
7:43am ET
Best-Performing Stocks of 2023: Can They Keep On Rolling?
No recent press releases are available for SLNO
SLNO Financials
Key terms
Ad Feedback
SLNO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SLNO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
